Moderna shares surged as much as 156% to about $161 on Wednesday after the company and Merck reported positive results from the first late-stage trial of an mRNA-based cancer therapy.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.